Health
Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals – News-Medical.Net
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe…
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate the safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.
Opaganib potentially minimizes the likelihood of resistance due to viral mutations by targeting a human cell component involved…
-
Noosa News9 hours agoHow Lily Steele-Park took her rapist to court and won
-
General23 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business14 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Business12 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025